RVP · Retractable Technologies, Inc.

Performance Summary

Retractable Technologies reported mixed results for FY2025 with revenue growth but continued losses. Net sales increased 15.8% to $38.3 million from $33.0 million in FY2024, driven by a 23.3% increase in unit sales. However, the company reported a net loss of $12.6 million, worsening from a $11.9 million loss in FY2024. The operating loss was $21.2 million, essentially unchanged from the $21.1 million loss in the prior year. Key non-operating items included $6.0 million in TIA income, $5.6 million in realized gains on securities sales, and $1.9 million in litigation proceeds, partially offset by a $5.0 million unrealized loss on securities. The company ended the year with $2.6 million in cash and cash equivalents, down from $4.2 million at the end of FY2024.

Revenue Analysis

Revenue growth was driven by both domestic and international markets. Domestic sales accounted for 84.2% of total revenue ($32.2 million), increasing 9.7% year-over-year, while international sales grew 64.0% to $6.0 million. Product-wise, syringes remained the dominant category at $24.9 million (65.1% of sales), EasyPoint needles contributed $11.9 million (31.2%), blood collection products added $1.4 million (3.6%), and other products accounted for $44,000 (0.1%). The company noted that domestic unit sales increased 3.6% while international unit volume surged 164.7%, though international revenue growth was tempered by discounted pricing. Three significant customers accounted for 53.9% of net sales ($20.6 million).

Margins & Profitability

Gross margin improved to 0.1% from -3.1% in FY2024, but remained minimal at $47,000. The improvement was constrained by $1.8 million in tariff expenses and discounted international pricing that negatively impacted margins. Cost of sales totaled $38.2 million, including $35.1 million in cost of manufactured product and $3.1 million in royalty expense to shareholder Thomas J. Shaw. Operating expenses increased 5.7% to $21.2 million, driven by a $954,000 impairment charge related to older syringe and tooling equipment, and increased sales and marketing expenses due to higher headcount. The impairment represented 4.5% of total operating expenses.

Cash Flow & Balance Sheet

Cash flow from operations was negative $7.1 million, primarily due to the net loss of $12.6 million, partially offset by non-cash adjustments including $7.8 million in depreciation and amortization and $8.4 million in deferred taxes. Investing activities generated $6.0 million in cash, with $37.1 million in proceeds from securities sales offsetting $30.5 million in securities purchases and $536,000 in property and equipment purchases. Financing activities used $567,000, mainly for debt repayments and preferred stock dividends. The balance sheet shows total assets of $142.6 million, including $34.4 million in investments and $79.2 million in property, plant and equipment. Total liabilities were $68.3 million, including $58.1 million in TIA-related long-term liabilities. Stockholders' equity stood at $74.4 million.

Outlook

The company faces significant headwinds from tariffs, with prevailing rates of 120% on most syringe and needle products imported from China as of March 2026. Management is working to mitigate tariff impacts by shifting manufacturing of 1mL, 3mL, and EasyPoint needles to domestic facilities and adapting equipment to produce 0.5mL syringes domestically by the second half of 2026. The company continues to operate under the TIA agreement until June 30, 2030, which requires maintenance of equipment and availability of capacity. Risk factors include uncertainty around future tariff rates, potential supply chain disruptions from reliance on Chinese manufacturers (62.6% of products in 2025), and competitive pressures from larger players like BD and Embecta. No products under development are expected to be commercially available in 2026.